CoChat

Predictive approaches for drug combination discovery in cancer

Open access
Madani Tonekaboni, Seyed Ali, Soltan Ghoraie, Laleh, Manem, Venkata Satya Kumar, Haibe-Kains, Benjamin · 2018 · Briefings in Bioinformatics
Cited by 115

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Drug combinations have been proposed as a promising therapeutic strategy to overcome drug resistance and improve efficacy of monotherapy regimens in cancer. This strategy aims at targeting multiple components of this complex disease. Despite the increasing number of drug combinations in use, many of them were empirically found in the clinic, and the molecular mechanisms underlying these drug combinations are often unclear. These challenges call for rational, systematic approaches for drug combination discovery. Although high-throughput screening of single-agent therapeutics has been successfully implemented, it is not feasible to test all possible drug combinations, even for a reduced subset of anticancer drugs. Hence, in vitro and in vivo screening of a large number of drug combinations are not practical. Therefore, devising computational methods to efficiently explore the space of drug combinations and to discover efficacious combinations has attracted a lot of attention from the scientific community in the past few years. Nevertheless, in the absence of consensus regarding the computational approaches used to predict efficacious drug combinations, a plethora of methods, techniques and hypotheses have been developed to date, while the research field lacks an elaborate categorization of the existing computational methods and the available data sources. In this manuscript, we review and categorize the state-of-the-art computational approaches for drug combination prediction, and elaborate on the limitations of these methods and the existing challenges. We also discuss about the recent pan-cancer drug combination data sets and their importance in revising the available methods or developing more performant approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/bib/bbw104

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 68

  1. Bozic, 2013, Evolutionary dynamics of cancer in response to targeted combination therapy, Elife, 2, e00747., 10.7554/eLife.00747 · DOI · Paper page
  2. DeVita, 1975, Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer, Cancer, 35, 98, 10.1002/1097-0142(197501)35:1<98::AID-CNCR2820350115>3.0.CO;2-B · DOI · Paper page
  3. Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  4. Gadzicki, 2005, BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib, Cancer Genet Cytogenet, 159, 164, 10.1016/j.cancergencyto.2004.09.021 · doi:10.1016/j.cancergencyto.2004.09.021
  5. Lim, 2014, Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21, J Thorac Oncol, 9, 506, 10.1097/JTO.0000000000000095 · DOI
  6. Fisher, 2012, Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma, Cancer Manag Res, 4, 243
  7. Sun, 2015, Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment, Acta Pharmacol Sin, 36, 1219, 10.1038/aps.2015.92 · DOI · Paper page
  8. Hochhaus, 2002, Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy, Leukemia, 16, 2190, 10.1038/sj.leu.2402741 · DOI · Paper page
  9. Apperley, 2007, Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia, Lancet Oncol, 8, 1018, 10.1016/S1470-2045(07)70342-X · DOI · Paper page
  10. Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to Gefitinib or Erlotinib, PLoS Med, 2, e17., 10.1371/journal.pmed.0020017 · DOI · Paper page
  11. Bardelli, 2010, Molecular mechanisms of resistance to Cetuximab and Panitumumab in Colorectal cancer, J Clin Oncol, 28, 1254, 10.1200/JCO.2009.24.6116 · DOI · Paper page
  12. Kummar, 2010, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Nat Rev Drug Discov, 9, 843, 10.1038/nrd3216 · DOI · Paper page
  13. Mathews Griner, 2014, High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells, Proc Natl Acad Sci USA, 111, 2349, 10.1073/pnas.1311846111 · DOI · Paper page
  14. Fidock, 2004, Antimalarial drug discovery: efficacy models for compound screening, Nat Rev Drug Discov, 3, 509, 10.1038/nrd1416 · DOI · Paper page
  15. Demidem, 1997, Chimeric Anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B Cell Lymphoma cell line to cell killing by Cytotoxic Drugs, Cancer Biother Radiopharm, 12, 177, 10.1089/cbr.1997.12.177 · DOI · Paper page
  16. Gillet, 2013, The clinical relevance of cancer cell lines, J Natl Cancer Inst, 105, 452, 10.1093/jnci/djt007 · DOI · Paper page
  17. Hidalgo, 2014, Patient-derived xenograft models: an emerging platform for translational cancer research, Cancer Discov, 4, 998, 10.1158/2159-8290.CD-14-0001 · DOI · Paper page
  18. Choi, 2014, Lessons from patient-derived xenografts for better in vitro modeling of human cancer, Adv Drug Deliv Rev, 79–80, 222, 10.1016/j.addr.2014.09.009 · DOI · Paper page
  19. Fang, 2015, Experimental design and statistical analysis for three-drug combination studies, Stat Methods Med Res
  20. Zinner, 2009, Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells, Mol Cancer Ther, 8, 521, 10.1158/1535-7163.MCT-08-0937 · DOI
  21. Li, 2015, Large-scale exploration and analysis of drug combinations, Bioinformatics, 31, 2007, 10.1093/bioinformatics/btv080 · DOI · Paper page
  22. Lee, 2012, CDA: combinatorial drug discovery using transcriptional response modules, PLoS One, 7, e42573., 10.1371/journal.pone.0042573 · DOI
  23. Parkkinen, 2014, Probabilistic drug connectivity mapping, BMC Bioinformatics, 15, 113., 10.1186/1471-2105-15-113 · DOI
  24. Huang, 2014, DrugComboRanker: drug combination discovery based on target network analysis, Bioinformatics, 30, i228, 10.1093/bioinformatics/btu278 · DOI · Paper page
  25. Sun, 2015, Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer, Nat Commun, 6, 8481, 10.1038/ncomms9481 · DOI · Paper page
  26. Zhao, 2011, Prediction of drug combinations by integrating molecular and pharmacological data, PLoS Comput Biol, 7, e1002323., 10.1371/journal.pcbi.1002323 · DOI · Paper page
  27. Tallarida, 2006, An overview of drug combination analysis with isobolograms, J Pharmacol Exp Ther, 319, 1, 10.1124/jpet.106.104117 · DOI · Paper page
  28. Chou, 1977, A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems, J Biol Chem, 252, 6438, 10.1016/S0021-9258(17)39978-7 · DOI · Paper page
  29. Chou, 1977, On the determination of availability of ligand binding sites in steady-state systems, J Theor Biol, 65, 345, 10.1016/0022-5193(77)90329-0 · DOI
  30. Chou, 1976, Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands, J Theor Biol, 59, 253, 10.1016/0022-5193(76)90169-7 · DOI · Paper page
  31. Chou, 1974, Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition, Mol Pharmacol, 10, 235, 10.1016/S0026-895X(25)13852-2 · DOI · Paper page
  32. Loewe, 1953, The problem of synergism and antagonism of combined drugs, Arzneimittelforschung, 3, 285
  33. Nordling, 1953, A new theory on the cancer-inducing mechanism, Br J Cancer, 7, 68, 10.1038/bjc.1953.8 · DOI · Paper page
  34. Finney, 1952, Probit Analysis, J Am Pharm Assoc, 41, 627
  35. Reed, 1928, The application of the logistic function to experimental data, J Phys Chem, 33, 760, 10.1021/j150299a014 · DOI · Paper page
  36. Loewe, 1926, Über Kombinationswirkungen, Archiv Für Experimentelle Pathologie Und Pharmakologie, 114, 313, 10.1007/BF01952257 · DOI · Paper page
  37. Grindey, 1975, Approaches to the rational combination of antimetabolites for cancer chemotherapy, Drug Design, 169, 10.1016/B978-0-12-060305-3.50010-2 · DOI
  38. Sartorelli, 1965, Approaches to the combination chemotherapy of transplantable Neoplasms, Prog Tumor Res, 228, 10.1159/000391373 · DOI
  39. Venditti, 1964, Drug synergism in antineoplastic chemotherapy, Adv Chemother, 397, 10.1016/B978-1-4831-9929-0.50013-9 · DOI
  40. Burger, 1964, Drugs in our society, J Med Chem, 7, 835, 10.1021/jm00336a055 · doi:10.1021/jm00336a055
  41. Veldstra, 1956, Synergism and potentiation with special reference to the combination of structural analogues, Pharmacol Rev, 8, 339, 10.1016/S0031-6997(25)06966-2 · DOI
  42. Bulusu, 2016, Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives, Drug Discov Today, 21, 225, 10.1016/j.drudis.2015.09.003 · DOI · Paper page
  43. Ryall, 2015, Systems biology approaches for advancing the discovery of effective drug combinations, J Cheminform, 7, 7, 10.1186/s13321-015-0055-9 · DOI · Paper page
  44. Lopez, 2016, Combine and conquer: challenges for targeted therapy combinations in early phase trials, Nat Rev Clin Oncol
  45. Chou, 1983, Analysis of combined drug effects: a new look at a very old problem, Trends Pharmacol Sci, 4, 450, 10.1016/0165-6147(83)90490-X · DOI · Paper page
  46. Ritz, 2005, Bioassay analysis using R, J Stat Softw, 12, 1, 10.18637/jss.v012.i05 · DOI · Paper page
  47. Dreβler, 1999, CombiTool—a new computer program for analyzing combination experiments with biologically active agents, Comput Biomed Res, 32, 145, 10.1006/cbmr.1999.1509 · DOI
  48. Smirnov, 2015, PharmacoGx: an R package for analysis of large pharmacogenomic datasets, Bioinformatics, 32, 1244, 10.1093/bioinformatics/btv723 · DOI · Paper page
  49. Laskey, 2014, A mechanistic theory to explain the efficacy of antiretroviral therapy, Nat Rev Microbiol, 12, 772, 10.1038/nrmicro3351 · DOI
  50. Li, 2014, Systems pharmacology strategies for drug discovery and combination with applications to cardiovascular diseases, J Ethnopharmacol, 151, 93, 10.1016/j.jep.2013.07.001 · DOI
  51. Wu, 2010, A systems biology approach to identify effective cocktail drugs, BMC Syst Biol, 4(Suppl 2), S7., 10.1186/1752-0509-4-S2-S7 · DOI
  52. Cunningham, 2009, Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer, J Clin Oncol, 27, 5513, 10.1200/JCO.2009.24.2446 · DOI · Paper page
  53. Marsh, 2015, Pancreatic cancer and FOLFIRINOX: a new era and new questions, Cancer Med, 4, 853, 10.1002/cam4.433 · DOI
  54. Wong, 2008, Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm, Proc Natl Acad Sci USA, 105, 5105, 10.1073/pnas.0800823105 · DOI · Paper page
  55. Sirota, 2011, Discovery and preclinical validation of drug indications using compendia of public gene expression data, Sci Transl Med, 3, 96ra77., 10.1126/scitranslmed.3001318 · DOI · Paper page
  56. Harrell, 1996, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors, Stat Med, 15, 361, 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
  57. Wei, 2006, Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance, Cancer Cell, 10, 331, 10.1016/j.ccr.2006.09.006 · DOI · Paper page
  58. Forrest, 1993, Genetic algorithms: principles of natural selection applied to computation, Science, 261, 872, 10.1126/science.8346439 · DOI · Paper page
  59. Bartlett, 1935, Contingency table interactions, Suppl J R Stat Soc, 2, 248, 10.2307/2983639 · DOI · Paper page
  60. Kang, 2015, Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach, Stat Med, 34, 685, 10.1002/sim.6370 · DOI · Paper page
  61. Tang, 2015, What is synergy? The Saariselkä agreement revisited, Front Pharmacol, 6, 181, 10.3389/fphar.2015.00181 · DOI · Paper page
  62. Greco, 1992, Consensus on concepts and terminology for combined-action assessment: the Saariselkä agreement, Arch Complex Environ Stud, 4, 65
  63. Safikhani, 2016, Assessment of pharmacogenomic agreement, 10.12688/f1000research.8705.1 · DOI
  64. Haverty, 2016, Reproducible pharmacogenomic profiling of cancer cell line panels, Nature, 533, 333, 10.1038/nature17987 · DOI · Paper page
  65. Hatzis, 2014, Enhancing reproducibility in cancer drug screening: how do we move forward?, Cancer Res, 74, 4016, 10.1158/0008-5472.CAN-14-0725 · DOI · Paper page
  66. Hebenstreit, 2012, Methods, challenges and potentials of single Cell RNA-seq, Biology, 1, 658, 10.3390/biology1030658 · DOI
  67. Marguerat, 2009, RNA-seq: from technology to biology, Cell Mol Life Sci, 67, 569, 10.1007/s00018-009-0180-6 · DOI · Paper page
  68. Szyf, 2009, Epigenetics, DNA methylation, and chromatin modifying drugs, Annu Rev Pharmacol Toxicol, 49, 243, 10.1146/annurev-pharmtox-061008-103102 · DOI · Paper page

Cited by

See all 115

Metadata

Authors
Madani Tonekaboni, S. A., Soltan Ghoraie, L., Manem, V. S. K., & Haibe-Kains, B.
Venue
Briefings in Bioinformatics
Published
2016-11-15
Volume
19
Issue
2
Pages
263-276
ISSN
  • 1467-5463 (ISSN-L)
  • 1477-4054
OpenAlex
W2551072359
Cited by
115
References
29
FWCI
5.06
Type
journal article
Language
en
Open access
bronze
Funders
  • Canadian Cancer Society Research Institute (#703886)
  • National Institutes of Health (#236136)
  • Canadian Institutes of Health Research
  • Natural Sciences and Engineering Research Council of Canada

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictive approaches for drug combination discovery in cancer. https://app.cochat.ai/papers/10.1093/bib/bbw104
The paper
Madani Tonekaboni, S. A., Soltan Ghoraie, L., Manem, V. S. K., & Haibe-Kains, B. (2018). Predictive approaches for drug combination discovery in cancer. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbw104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.